Exo-miR-1290-induced by COX-2 overexpression promotes cancer-associated fibroblasts activation and tumor progression by CUL3-Nrf2 pathway in lung adenocarcinoma

被引:16
作者
Bai, Xiaoming [1 ]
Shao, Jiaofang [2 ]
Duan, Tinghong [1 ]
Liu, Xue [1 ]
Wang, Min [1 ]
Li, Xuanya [1 ]
You, Qiang [3 ]
Zhang, Zhiyuan [1 ]
Pan, Jinshun [3 ]
机构
[1] Nanjing Med Univ, Dept Pathol, 101 Longmian Ave, Nanjing 211166, Peoples R China
[2] Nanjing Med Univ, Dept Bioinformat, 101 Longmian Ave, Nanjing 211166, Peoples R China
[3] Nanjing Med Univ, Dept Biotherapy, Affiliated Hosp 2, Nanjing 210011, Peoples R China
关键词
COX-2; Exo-miR-1290; CUL3; Nrf2; CAFs activation; LUAD; MIR-1290; NRF2; METASTASIS; EXPRESSION; BIOMARKER; NSCLC;
D O I
10.1186/s12964-023-01268-0
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
BackgroundCancer-associated fibroblasts (CAFs) are critically involved in tumor progression by maintaining extracellular mesenchyma (ECM) production and improving tumor development. Cyclooxygenase-2 (COX-2) has been proved to promote ECM formation and tumor progression. However, the mechanisms of COX-2 mediated CAFs activation have not yet been elucidated. Therefore, we conducted this study to identify the effects and mechanisms of COX-2 underlying CAFs activation by tumor-derived exosomal miRNAs in lung adenocarcinoma (LUAD) progression.MethodsAs measures of CAFs activation, the expressions of fibroblasts activated protein-1 (FAP-1) and & alpha;-smooth muscle actin (& alpha;-SMA), the main CAFs markers, were detected by Western blotting and Immunohistochemistry. And the expression of Fibronectin (FN1) was used to analyze ECM production by CAFs. The exosomes were extracted by ultracentrifugation and exo-miRNAs were detected by qRT-PCR. Herein, we further elucidated the implicated mechanisms using online prediction software, luciferase reporter assays, co-immunoprecipitation, and experimental animal models.ResultsIn vivo, a positive correlation was observed between the COX-2 expression levels in parenchyma and & alpha;-SMA/FN1 expression levels in mesenchyma in LUAD. However, PGE2, one of major product of COX-2, did not affect CAFs activation directly. COX-2 overexpression increased exo-miR-1290 expression, which promoted CAFs activation. Furthermore, Cullin3 (CUL3), a potential target of miR-1290, was found to suppress COX-2/exo-miR-1290-mediated CAFs activation and ECM production, consequently impeding tumor progression. CUL3 is identified to induce the Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2, Nrf2) ubiquitination and degradation, while exo-miR-1290 can prevent Nrf2 ubiquitination and increase its protein stability by targeting CUL3. Additionally, we identified that Nrf2 is direcctly bound with promoters of FAP-1 and FN1, which enhanced CAFs activation by promoting FAP-1 and FN1 transcription.ConclusionsOur data identify a new CAFs activation mechanism by exosomes derived from cancer cells that overexpress COX-2. Specifically, COX-2/exo-miR-1290/CUL3 is suggested as a novel signaling pathway for mediating CAFs activation and tumor progression in LUAD. Consequently, this finding suggests a novel strategy for cancer treatment that may tackle tumor progression in the future.Bur-ecQNwLXz_ZNAmX2E1RVideo AbstractConclusionsOur data identify a new CAFs activation mechanism by exosomes derived from cancer cells that overexpress COX-2. Specifically, COX-2/exo-miR-1290/CUL3 is suggested as a novel signaling pathway for mediating CAFs activation and tumor progression in LUAD. Consequently, this finding suggests a novel strategy for cancer treatment that may tackle tumor progression in the future.Bur-ecQNwLXz_ZNAmX2E1RVideo Abstract
引用
收藏
页数:19
相关论文
共 48 条
[1]
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice [J].
Albrengues, Jean ;
Shields, Mario A. ;
Ng, David ;
Park, Chun Gwon ;
Ambrico, Alexandra ;
Poindexter, Morgan E. ;
Upadhyay, Priya ;
Uyeminami, Dale L. ;
Pommier, Arnaud ;
Kuttner, Victoria ;
Bruzas, Emilis ;
Maiorino, Laura ;
Bautista, Carmelita ;
Carmona, Ellese M. ;
Gimotty, Phyllis A. ;
Fearon, Douglas T. ;
Chang, Kenneth ;
Lyons, Scott K. ;
Pinkerton, Kent E. ;
Trotman, Lloyd C. ;
Goldberg, Michael S. ;
Yeh, Johannes T. -H. ;
Egeblad, Mikala .
SCIENCE, 2018, 361 (6409) :1353-+
[2]
CANCER-ASSOCIATED FIBROBLASTS CONTRIBUTE TO PDAC HETEROGENEITY [J].
不详 .
CANCER DISCOVERY, 2019, 9 (08) :993-993
[3]
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas [J].
Campbell, Joshua D. ;
Alexandrov, Anton ;
Kim, Jaegil ;
Wala, Jeremiah ;
Berger, Alice H. ;
Pedamallu, Chandra Sekhar ;
Shukla, Sachet A. ;
Guo, Guangwu ;
Brooks, Angela N. ;
Murray, Bradley A. ;
Imielinski, Marcin ;
Hu, Xin ;
Ling, Shiyun ;
Akbani, Rehan ;
Rosenberg, Mara ;
Cibulskis, Carrie ;
Ramachandran, Aruna ;
Collisson, Eric A. ;
Kwiatkowski, David J. ;
Lawrence, Michael S. ;
Weinstein, John N. ;
Verhaak, Roel G. W. ;
Wu, Catherine J. ;
Hammerman, Peter S. ;
Cherniack, Andrew D. ;
Getz, Gad ;
Artyomov, Maxim N. ;
Schreiber, Robert ;
Govindan, Ramaswamy ;
Meyerson, Matthew .
NATURE GENETICS, 2016, 48 (06) :607-+
[4]
Turning foes to friends: targeting cancer-associated fibroblasts [J].
Chen, Xueman ;
Song, Erwei .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (02) :99-115
[5]
Clinical and therapeutic relevance of cancer-associated fibroblasts [J].
Chen, Yang ;
McAndrews, Kathleen M. ;
Kalluri, Raghu .
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) :792-804
[6]
The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression [J].
Cho, Jaebeom ;
Lee, Hyo-Jong ;
Hwang, Su Jung ;
Min, Hye-Young ;
Kang, Han Na ;
Park, A-Young ;
Hyun, Seung Yeob ;
Sim, Jeong Yeon ;
Lee, Ho Jin ;
Jang, Hyun-Ji ;
Suh, Young-Ah ;
Hong, Sungyoul ;
Shin, Young Kee ;
Kim, Hye Ryun ;
Lee, Ho-Young .
CANCER RESEARCH, 2020, 80 (11) :2257-2272
[7]
NRF2 and the Hallmarks of Cancer [J].
de la Vega, Montserrat Rojo ;
Chapman, Eli ;
Zhang, Donna D. .
CANCER CELL, 2018, 34 (01) :21-43
[8]
MALIGNANT TRANSFORMATION OF MOUSE PRIMARY KERATINOCYTES BY HARVEY SARCOMA-VIRUS AND ITS MODULATION BY SURROUNDING NORMAL-CELLS [J].
DOTTO, GP ;
WEINBERG, RA ;
ARIZA, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (17) :6389-6393
[9]
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non-Small-Cell Lung Cancer [J].
Edelman, Martin J. ;
Tan, Ming T. ;
Fidler, Mary J. ;
Sanborn, Rachel E. ;
Otterson, Greg ;
Sequist, Lecia V. ;
Evans, Tracey L. ;
Schneider, Bryan J. ;
Keresztes, Roger ;
Rogers, John S. ;
de Mayolo, Jorge Antunez ;
Feliciano, Josephine ;
Yang, Yang ;
Medeiros, Michelle ;
Zaknoen, Sara L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :189-U96
[10]
PGE2 in fibrosis and cancer: Insights into fibroblast activation [J].
Elwakeel, Eiman ;
Bruene, Bernhard ;
Weigert, Andreas .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2019, 143